Integrating cheminformatics and phenotypic screening: A novel approach for enhanced mode of action prediction

Format:

About the poster

At Bio-IT World 2024, Ardigen presented a novel approach to enhance Mode of Action (MoA) prediction by combining chemical structure and phenotypic screening data. Using deep learning techniques, the team developed a multimodal model that integrates features from High Content Screening (HCS) images and compound structures. This fusion significantly outperformed traditional, human-defined descriptors—demonstrating higher prediction accuracy and faster inference times.

The study leveraged open-source datasets and proprietary AI models to show that combining visual and structural data yields a synergistic effect, enabling more reliable drug discovery outcomes. This work marks a major step forward in phenotypic screening, showcasing Ardigen’s commitment to advancing AI-powered solutions in life sciences.

Want to know more?

You might be also interested in:

Accelerating biomarker discovery through omic data integration into drug screens
Accelerating biomarker discovery through omic data integration
Two scientists observing AI-driven cell analysis on a digital screen, representing decision-making in biotech innovation.
Build or Buy? Strategic Considerations for Biotech Companies Implementing AI Solutions
biotech US market
AI in biotech: What the US market got right (and what it’s still learning)
From Data Chaos to Drug Discovery – Ardigen Talk at NextGen Omics Conference

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!